XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2Close
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenues, net $ 0 $ 475 Close
Operating expenses:    
Cost of product sales (80) 551
Research and development 2,116 6,008
Acquired in-process research and development 27,538 0
General and administrative 3,193 2,708
Total operating expenses 32,767 9,267 Close
Total operating income (loss) (32,767) (8,792)
Other expense:    
Excess of warrant fair value over private placement proceeds (79,276) 0
Private placement transaction costs (9,220) 0
Change in fair value of derivative liability (120) (180)
Interest income, net 100 (949)
Other expense, net 0 (26)
Total other expense, net (88,516) (1,155) Close
Loss before taxes (121,283) (9,947) Close
Income tax expense 7 8 Close
Net loss (121,290) (9,955) Close
Comprehensive loss $ (121,290) $ (9,955)
Net loss per share of common stock, basic (in dollars per share) [1] $ (141) $ (204)
Net loss per share of common stock, diluted (in dollars per share) [1] $ (141) $ (204)
Product revenue, net    
Revenues:    
Total revenues, net $ 0 $ 475
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.